2000;6(5):440C449

2000;6(5):440C449. which encompasses three functional domains. Domain name I binds the 2-macroglobulin receptor, which is usually ubiquitously expressed in normal tissues; the exotoxin-2-macroglobulin receptor complex undergoes internalization by endocytosis 45. Domain name II is a site of PSI-6206 proteolytic cleavage that activates PE and is required for catalyzing the translocation of the catalytic domain III into the cytosol. Once in the PSI-6206 cytosol, Domain name III directs the processed fragment of the toxin to the endoplasmic reticulum where it inactivates the elongation factor 2 through ADP ribosylation, inhibiting protein synthesis and leading to cell death 45. The mutant exotoxin, PE38QQR 46, does not bind to the ubiquitous 2-macroglobulin receptor due to the deletion of domain name I 46, hence it can be linked to numerous ligands in order to promote its internalization into target tumor cells. To target the PE toxin to human glioma cells, a fusion protein was constructed that links the N-terminal domain name of PE38QQR to native hIL-13 (hIL-13-PE, in reactive astrocytes surrounding human astrocytoma specimens 59. These findings suggest that the specificity of the hIL-13-PEQQR may be lower than hitherto anticipated. In fact, clinical trials in GBM patients showed that intracranial administration of hIL-13-PE38QQR led to dose limiting toxicities in some patients, including neurological symptoms secondary to necrotic and inflammatory processes as well as irreversible hemiparesis and the death of one patient due to neurologic decline possibly related to Cintredekin Besudotox 56. Grade III and IV imaging changes were observed in tumor infiltrated and normal brain parenchyma that were indicative of tissue damage 60. Brain tissue damage was regarded as a result of nonspecific internalization of hIL-13-PE38QQR by normal brain cells 56. In fact, we have recently exhibited that a single injection of hIL-13-PE38QQR into the na?ve mouse brain prospects to acute neurological deterioration and severe neuropathological changes, even at low doses 50. To enhance the targeting of the toxin to the GBM-associated IL-13R2, the IL-13 gene has been engineered to generate a mutant form of IL-13 (mhIL-13, IL-13.E13K) 61. It has been shown that IL13.E13K fused to PE (mhIL-13-PE) binds to GBM-associated IL132R with 50-fold higher affinity compared to native hIL-13 61, 62. Importantly, unlike its native counterpart, mhIL13-PE does not interact with the physiological IL13/IL4R 61, 62, hence, decreasing the capacity of the chimeric toxin to bind to normal cells. Although PSI-6206 this second-generation cytotoxin exerts a stronger anti-tumor effect than first-generation hIL-13-PE in intracranial human GBM models, its administration into na?ve mouse brain prospects to dose-dependent neurotoxicity 50. In a recent publication from our lab, we showed the development of a novel third-generation IL-13-based cytotoxin 50. We developed an adenoviral vector (Ad, Fig. 2) encoding mhIL13-PE to provide long-term high local expression of the targeted toxin, leading to an effective cytotoxic response in IL-13R2-expressing GBM cells without adverse side effects to surrounding normal brain tissue. Rabbit polyclonal to ZNF280A The expression of mhIL-13 fused to PE toxin from an Ad vector allows direct and continued targeting of mhIL-13-PE to GBM cells when compared to lacR-IPTG system 65. While the first PSI-6206 generation Tet system fails to completely inhibit transgene expression in the OFF state 67, the third generation Tet system used by us constitutes a non leaky inducible system ideal for delivering such harmful genes. Another approach to increase the specificity and reduce the toxicity of targeted toxins is to express them under the control of a cell-type specific` PSI-6206 promoter. Native DT expressed under the control of a prostate specific antigen (PSA) promoter and delivered using an Ad vector in a mouse model of prostate malignancy led to ~80% long term survival 68. However, transgene expression is much higher when driven by ubiquitous promoters than when using cell-type specific promoters 69, 70. The use of strong promoters elicits high transgene expression levels using low doses of Ads, which minimizes the risk of neurotoxicity due to high viral vector loads 71, 72. Considering that the specificity of our approach relies on the targeting of mIL-13-PE to IL-13R2, which is only expressed in GBM cells and absent in the normal brain, we expressed the components of the Tet-ON system under the control of the potent murine CMV promoter 50. We have previously exhibited that this promoter elicits high.